| ID | 1247 |
| Name of the vaccine | Tritanrix-HepB/Hib-MenAC |
| Microbe | Bacteria |
| Disease name | Diphtheria |
| Name of bacteria | Corynebacterium diphtheriae |
| Type of vaccine | Combination |
| Nucleic acid content | DNA |
| Age | 427 to 730 days |
| Description of the vaccine | Combined diphtheria, tetanus, whole cell pertussis, hepatitis B, haemophilus influenzae type b meningococcal AC-tetanus toxoid conjugate vaccine. |
| Name of the manufacturer | GlaxoSmithKline |
| Name of the manufacturing country | Thailand |
| Year of manufacture | 2006 |
| Clinical Phase status | Clinical - Phase 3 |
| Bacterial strain | Gram-positive bacillus. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | Three doses and a booster. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | For whole cell pertussis, haemophilus influenzae type b, tetanus and hepatitis B. |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination (4 doses) |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT00136604 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|